Researchers found that the aminoglycoside antibiotics G418 and gentamicin enabled nerve cells with a genetic mutation that prevents progranulin protein production, which is evident in people with frontotemporal dementia, to recover up to 50% to 60% of progranulin levels. The study in Human Molecular Genetics "provides an important proof of concept that these aminoglycoside antibiotics or their derivatives can be a therapeutic avenue for frontotemporal dementia," said researcher Haining Zhu.
Aminoglycoside antibiotics show promise in frontotemporal dementia
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.